Correlation of in vivo and in vitro release data for rh-INFα lipid implants

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 70, Issue 2, 2008, Pages 690-694

  Schwab, M ^a   Kessler, B ^a   Wolf, E ^a   Jordan, G ^b   Mohl, S ^b   Winter, G ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

Computer modeling; In vivo in vitro correlation; Lipid implants; Protein release

Indexed keywords

DYNASAN 118; LIPID; RECOMBINANT ALPHA INTERFERON; TRISTEARIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG HALF LIFE; DRUG IMPLANT; DRUG RELEASE; FEMALE; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN SECRETION; PROTEIN STABILITY; SUSTAINED DRUG RELEASE;

ANIMALS; COMPUTER SIMULATION; DRUG IMPLANTS; FEMALE; INTERFERON ALFA-2A; MATERIALS TESTING; RABBITS; SOLUBILITY; TRIGLYCERIDES;

EID: 52949099198     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.05.010     Document Type: Article

References (10)

1. Sinha V.R., and Trehan A. Biodegradable microspheres for protein delivery. J. Control. Release 90 (2003) 261-280
2. Morlock M., Koll H., Winter G., and Kissel T. Microencapsulation of rh-erythropoietin, using biodegradable poly(d,l-lactide-co-glycolide). Protein stability and the effects of stabilizing excipients. Eur. J. Pharm. Biopharm. 43 (1997) 29-36
3. Mohl S., and Winter G. Continuous release of rh-interferon alpha-2a from triglyceride matrices. J. Control. Release 97 (2004) 67-78
4. Reithmeier H., Herrmann J., and Göpferich A. Lipid microparticles as a parenteral controlled release device for peptides. J. Control. Release 73 (2001) 339-350
5. Vogelhuber W., Magni E., Mouro M., Spruss T., Guse C., Gazzaniga A., and Göpferich A. Monolithic triglyceride matrices: a controlled-release system for proteins. Pharm. Dev. Technol. 8 1 (2003) 71-79
6. Mohl S., and Winter G. Continuous release of rh-interferon (alpha-2a) from triglyceride implants: storage stability of the dosage forms. Pharm. Dev. Technol. 11 (2006) 103-110
7. Herrmann S., Mohl S., Siepmann F., Siepmann J., and Winter G. New insight into the role of polyethylene glycol acting as protein release modifier in lipidic implants. Pharm. Res. 24 8 (2007) 1527-1537
8. Trown P.W., Wills R.J., and Kamm J.J. The preclinical development of Roferon - A. Roche Res. Cent., Nutley, NJ, USA. Cancer (NY, United States) 57 Suppl. 8 (1986) 1648-1656
9. A. Ring, Einfluß der Modellwahl auf die Zuverlässigkeit der Schätzung pharmakokinetischer Parameter, Dissertation, S. 25 (2001). Available from: .
10. BPI Service GmbH, Fachinfo-Service. Postfach 1255, 88322 Aulendorf; Roferon-A, Summary of Medicinal Product Characteristics, 2003.